Tiotropium Add-On and Treatable Traits in Asthma-COPD Overlap: A Real-World Pilot Study

Overview

Journal J Asthma Allergy

Publisher Dove Medical Press

Date 2022 Jun 2

PMID 35651483

Authors

Yoshihisa Ishiura

Masaki Fujimura

Noriyuki Ohkura

Johsuke Hara

Kahori Nakahama

Yusuke Sawai

Takeshi Tamaki

Ryuta Murai

Toshiki Shimizu

Naoyuki Miyashita

Shosaku Nomura

Affiliations

Soon will be listed here.

Abstract

Purpose: The 'treatable traits' strategy for patients with chronic inflammatory airway diseases, especially asthma and chronic obstructive pulmonary disease (COPD), is a focus of interest, because it implements precision and personalized medicine. Asthma-COPD overlap (ACO), a phenotype involving both asthma and COPD, is an important disease entity because patients with ACO have significantly worse outcomes, conferring greater economical and social burdens. Some guidelines for ACO recommend add-on therapy of long-acting muscarinic antagonists to inhaled corticosteroids and long-acting β agonists. However, this approach is based on extrapolation from patients with asthma or COPD alone. Consequently, a 'treatable traits' approach suitable for ACO remains obscure.

Methods: A 12-week open-label cross-over pilot study was conducted in patients with ACO to investigate the effect of tiotropium bromide (TIO) 5 µg/day add-on therapy to fluticasone propionate/formoterol fumarate (FP/FM) 500/20 µg/day compared with FP/FM 500/20 µg/day alone. A 4-week run-in period and two 4-week treatment periods were included.

Results: A total of 18 male patients with stable ACO participated in this pilot study. All patients were ex-smokers. Mean values ± standard deviation (SD) for forced expiratory volume in 1 second (FEV) were 1.21 ± 0.49 L after the run-in period, 1.20 ± 0.51 L after the FP/FM combination therapy period, and 1.30 ± 0.48 L after the TIO add-on therapy to FP/FM period. FEV values after the TIO add-on therapy FP/FM period were significantly higher than those after the run-in period ( < 0.01).

Conclusion: TIO add-on therapy to FP/FM in patients with ACO, considered difficult to treat because of the presence of both asthma and COPD, resulted in improvements in lung function parameters in this real-world pilot study, indicating the potential value of TIO add-on therapy as a "treatable traits" option for standard treatment for ACO.

Citing Articles

Using inflammatory index to distinguish asthma, asthma-COPD overlap and COPD: A retrospective observational study.

Ma H, Yang L, Liu L, Zhou Y, Guo X, Wu S Front Med (Lausanne). 2022; 9:1045503.

PMID: 36465915 PMC: 9714673. DOI: 10.3389/fmed.2022.1045503.

References

Cazzola M, Ora J, Rogliani P, Matera M . Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017; 11(3):239-253. DOI: 10.1080/17476348.2017.1289844. View

Corren J, Mansfield L, Pertseva T, Blahzko V, Kaiser K . Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respir Med. 2013; 107(2):180-95. DOI: 10.1016/j.rmed.2012.10.025. View

McDonald V, Osadnik C, Gibson P . Treatable traits in acute exacerbations of chronic airway diseases. Chron Respir Dis. 2019; 16:1479973119867954. PMC: 6696844. DOI: 10.1177/1479973119867954. View

Wise R, Anzueto A, Cotton D, Dahl R, Devins T, Disse B . Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013; 369(16):1491-501. DOI: 10.1056/NEJMoa1303342. View

Alving K, Janson C, Nordvall L . Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children. Respir Res. 2006; 7:67. PMC: 1462993. DOI: 10.1186/1465-9921-7-67. View

Soriano J, Visick G, Muellerova H, Payvandi N, Hansell A . Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005; 128(4):2099-107. DOI: 10.1378/chest.128.4.2099. View

Marsh S, Travers J, Weatherall M, Williams M, Aldington S, Shirtcliffe P . Proportional classifications of COPD phenotypes. Thorax. 2008; 63(9):761-7. PMC: 2862964. DOI: 10.1136/thx.2007.089193. View

Papi A, Mansur A, Pertseva T, Kaiser K, McIver T, Grothe B . Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations. J Aerosol Med Pulm Drug Deliv. 2016; 29(4):346-61. PMC: 4965704. DOI: 10.1089/jamp.2015.1255. View

Werner C, Linde K, Schaffner J, Storr C, Schneider A . Weekly self-measurement of FEV1 and PEF and its impact on ACQ (asthma control questionnaire)-scores: 12-week observational study with 76 patients. NPJ Prim Care Respir Med. 2017; 27(1):64. PMC: 5722863. DOI: 10.1038/s41533-017-0064-4. View

10.

McDonald V, Clark V, Cordova-Rivera L, Wark P, Baines K, Gibson P . Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J. 2019; 55(3). DOI: 10.1183/13993003.01509-2019. View

11.

Matza L, Park J, Coyne K, Skinner E, Malley K, Wolever R . Derivation and validation of the ASK-12 adherence barrier survey. Ann Pharmacother. 2009; 43(10):1621-30. DOI: 10.1345/aph.1M174. View

12.

Jarjour N, Erzurum S, Bleecker E, Calhoun W, Castro M, Comhair S . Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 2011; 185(4):356-62. PMC: 3297096. DOI: 10.1164/rccm.201107-1317PP. View

13.

To T, Stanojevic S, Moores G, Gershon A, Bateman E, Cruz A . Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012; 12:204. PMC: 3353191. DOI: 10.1186/1471-2458-12-204. View

14.

Ishiura Y, Fujimura M, Yamamoto H, Ishiguro T, Ohkura N, Myou S . COX-2 inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma. J Investig Allergol Clin Immunol. 2009; 19(5):370-4. View

15.

Mackay A, Donaldson G, Patel A, Jones P, Hurst J, Wedzicha J . Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med. 2012; 185(11):1218-24. DOI: 10.1164/rccm.201110-1843OC. View

16.

Chari V, McIvor R . Tiotropium for the Treatment of Asthma: Patient Selection and Perspectives. Can Respir J. 2018; 2018:3464960. PMC: 5833870. DOI: 10.1155/2018/3464960. View

17.

Park H, Song W . Sex and Treatable Traits in Severe Asthma. Allergy Asthma Immunol Res. 2021; 13(2):167-170. PMC: 7840866. DOI: 10.4168/aair.2021.13.2.167. View

18.

Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K . The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003; 22(6):1026-41. DOI: 10.1183/09031936.03.00089403. View

19.

Doherty D, Bleecker E, Moroni-Zentgraf P, Zaremba-Pechmann L, Kerstjens H . Tiotropium Respimat Efficacy and Safety in Asthma: Relationship to Age. J Allergy Clin Immunol Pract. 2020; 8(8):2653-2660.e4. DOI: 10.1016/j.jaip.2020.04.013. View

20.

Mori K, Shirai T, Mikamo M, Shishido Y, Akita T, Morita S . Colored 3-dimensional analyses of respiratory resistance and reactance in COPD and asthma. COPD. 2011; 8(6):456-63. DOI: 10.3109/15412555.2011.626818. View